Applied Clinical Trials

Applied Clinical Trials magazine is an internationally recognized, peer-reviewed publication that focuses on the management of clinical trials. It highlights the collaboration between pharmaceutical developers and the medical researchers who conduct rigorous tests on new medications, all within a tightly regulated environment.

National

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#826940

United States

#342052

Health/Biotechnology and Pharmaceuticals

#328

Traffic sources

Monthly visitors

Articles

Uplizna Shows Significant Efficacy, Safety Treating Generalized Myasthenia Gravis in Phase III MINT Trial

1 week ago | appliedclinicaltrialsonline.com | Davy James

Findings from the Phase III MINT clinical trial (NCT04524273) show that Uplizna (inebilizumab) produced significant short-term clinical improvements in patient- and clinician-assessed outcomes with a tolerable safety profile among adults with generalized myasthenia gravis (gMG).
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial

1 week ago | appliedclinicaltrialsonline.com | Davy James

Long-term safety and efficacy clinical trial data (NCT03307980) for patients with hemophilia B administered the recombinant adeno-associated virus (AAV) vector gene therapy Beqvez (fidanacogene elaparvovec) show sustained factor IX expression, low bleeding rates, and generally favorable safety outcomes.
DapaTAVI Trial Shows Farxiga Significantly Lowers Risk of Death After Transcatheter Aortic-Valve Implantation in Older Patients

1 week ago | appliedclinicaltrialsonline.com | Davy James

Results from the Phase IV DapaTAVI trial (NCT04696185) show that the addition of Farxiga (dapagliflozin) to standard care in older patients with severe aortic stenosis undergoing transcatheter aortic-valve implantation (TAVI) lowered the risk of death or worsening heart failure by 28%.
2025 Rally for Rare: Bringing the Rare Disease Community Together

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

In a recent video interview with Applied Clinical Trials, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discussed the unique challenges in rare disease R&D, including competing priorities among researchers, difficulty in diagnosing and treating patients, and defining endpoints due to varying symptoms.
Johnson & Johnson’s Icotrokinra Succeeds in Phase III Trial for Plaque Psoriasis in Adolescents

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

Johnson & Johnson has shared positive data from a subgroup analysis of the Phase III ICONIC-LEAD clinical trial of its investigational icotrokinra for the treatment of moderate-to-severe plaque psoriasis.
Phase III HERCULES Trial Shows Tolebrutinib Significantly Slows Disability Progression in Non-Relapsing Secondary Progressive MS

1 week ago | appliedclinicaltrialsonline.com | Davy James

Findings from the Phase III HERCULES trial (NCT04411641) published by The New England Journal of Medicine (NEJM) show tolebrutinib (Sanofi) significantly delayed disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).1,2 Investigators said these results demonstrate the potential of tolebrutinib as a first-in-class, brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor in treating nrSPMS, which currently lacks any FDA-approved treatments.
The Role of Collaboration in Advancing Rare Disease Research

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

April 15, 2025By In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, talks collaboration and maximizing resources among the various stakeholders in rare disease research.
Unique Challenges in Rare Disease Research

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

In a recent video interview with Applied Clinical Trials, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discussed the unique challenges in rare disease R&D, including competing priorities among researchers, difficulty in diagnosing and treating patients, and defining endpoints due to varying symptoms.
Phase III EXPECTS Trial Finds Alteplase Boosts 90-Day Recovery in Posterior Circulation Stroke Patients

1 week ago | appliedclinicaltrialsonline.com | Davy James

Findings from the Phase III EXPECTS clinical trial (NCT05429476) show that in patients experiencing a mostly mild posterior circulation stroke who are not candidates for thrombectomy, treatment with alteplase administered 4.5 to 24 hours following stroke onset produced a higher rate of functional independence at 90 days compared to standard care.
Maintaining Regulatory Adherence with Clinical Technology

2 weeks ago | appliedclinicaltrialsonline.com | Andy Studna

April 11, 2025By In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, highlights the need for maintaining data privacy in a highly regulated clinical research industry. In a recent video interview with Applied Clinical Trials, Theirry Escudier, Portfolio Lead, Pistoia Alliance, discussed the alliance’s newest initiative to assess the carbon footprint of clinical trials.